

Darren Brenner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6500258/publications.pdf>

Version: 2024-02-01

47
papers

1,339
citations

516561

16
h-index

345118

36
g-index

48
all docs

48
docs citations

48
times ranked

1302
citing authors

#	ARTICLE	IF	CITATIONS
1	Re-evaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e682-e695.	2.4	5
2	Heterogeneity of primary and secondary peristalsis in systemic sclerosis: A new model of œscleroderma esophagus. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14284.	1.6	3
3	Opioid-Related Constipation. <i>Gastroenterology Clinics of North America</i> , 2022, 51, 107-121.	1.0	3
4	The Pelvic Floor: Complex Interplay Between Gastrointestinal and Urogenital Structures and Function. <i>Gastroenterology Clinics of North America</i> , 2022, 51, xv-xvi.	1.0	0
5	Real-World Treatment Strategies to Improve Outcomes in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation. <i>American Journal of Gastroenterology</i> , 2022, 117, S21-S26.	0.2	7
6	Best Practices for the Management of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation: A Roundtable Discussion and Review. <i>American Journal of Gastroenterology</i> , 2022, 117, S1-S1.	0.2	0
7	Mechanisms of Action of Current Pharmacologic Options for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation. <i>American Journal of Gastroenterology</i> , 2022, 117, S6-S13.	0.2	9
8	Effective Communication Strategies and Tools for Improving Treatment Outcomes in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation. <i>American Journal of Gastroenterology</i> , 2022, 117, S14-S20.	0.2	2
9	Mast cell activation in the systemic sclerosis esophagus. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 77-86.	1.0	1
10	The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies. <i>Supportive Care in Cancer</i> , 2021, 29, 5209-5218.	1.0	3
11	Baseline Predictors of Discontinuation of Prescription Drug Therapy for IBS-C: Cohort Analysis at an Integrated Healthcare System. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	1
12	A237 IMPROVEMENT IN ABDOMINAL SYMPTOMS WITH LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION: RESULTS FROM A PHASE 3B TRIAL. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 287-288.	0.1	0
13	Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 469-477.	0.5	0
14	Evaluating the Impact of Cost on the Treatment Algorithm for Chronic Idiopathic Constipation: Cost-Effectiveness Analysis. <i>American Journal of Gastroenterology</i> , 2021, 116, 2118-2127.	0.2	11
15	Focus on Pharmacotherapy for Irritable Bowel Syndrome with Constipation. <i>Gastroenterology Clinics of North America</i> , 2021, 50, 639-653.	1.0	2
16	ACG Clinical Guideline: Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021, 116, 17-44.	0.2	341
17	Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 469-477.	0.5	0
18	Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. <i>Advances in Therapy</i> , 2020, 37, 83-96.	1.3	28

#	ARTICLE	IF	CITATIONS
19	Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancer pain. <i>Pain Management</i> , 2020, 10, 301-306.	0.7	3
20	How to Manage Opioid-Related Constipation in Individuals With Chronic Nonmalignant Pain Syndromes. <i>American Journal of Gastroenterology</i> , 2020, 115, 307-310.	0.2	4
21	Response to Black et al.. <i>American Journal of Gastroenterology</i> , 2020, 115, 484-485.	0.2	1
22	Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study. <i>Pain</i> , 2020, 161, 1027-1036.	2.0	8
23	A6 EFFECTS OF ELUXADOLINE TREATMENT ON ABDOMINAL AND BOWEL SYMPTOMS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA REPORTING INADEQUATE SYMPTOM CONTROL WITH LOPERAMIDE: AGGREGATED RESULTS FROM PHASE 3 AND 4 CLINICAL TRIALS. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 8-9.	0.1	1
24	Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. <i>Gut</i> , 2019, 68, 434-444.	6.1	49
25	A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation. <i>American Journal of Gastroenterology</i> , 2019, 114, 954-963.	0.2	13
26	A44 ELUXADOLINE FOR THE TREATMENT OF ABDOMINAL PAIN IN ADULTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME WHO REPORT INADEQUATE RESPONSE TO LOPERAMIDE. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 88-89.	0.1	0
27	Food-related quality of life in patients with inflammatory bowel disease and irritable bowel syndrome. <i>Quality of Life Research</i> , 2019, 28, 2195-2205.	1.5	39
28	Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 1502-1511.	0.2	39
29	Fecal Microbiota Transplant for Irritable Bowel Syndrome: Panacea or Placebo?. <i>American Journal of Gastroenterology</i> , 2019, 114, 1032-1033.	0.2	5
30	Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up. <i>American Journal of Gastroenterology</i> , 2019, 114, 330-338.	0.2	39
31	Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13331.	1.6	3
32	Gut Microbiota-Based Therapies for Irritable Bowel Syndrome. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e134.	1.3	32
33	Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2018, 155, 47-57.	0.6	120
34	(Canâ€™t Get No) Patient Satisfaction. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 614-621.	1.1	11
35	Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13247.	1.6	20
36	Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy. <i>Journal of Pain Research</i> , 2018, Volume 11, 195-199.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Opioid-Related Constipation in Patients With Non-cancer Pain Syndromes: a Review of Evidence-Based Therapies and Justification for a Change in Nomenclature. <i>Current Gastroenterology Reports</i> , 2017, 19, 12.	1.1	29
38	The First Case of Mumps-Associated Achalasia. <i>American Journal of Gastroenterology</i> , 2017, 112, 1755-1756.	0.2	1
39	Chronic Constipation. <i>Gastroenterology Clinics of North America</i> , 2016, 45, 205-216.	1.0	16
40	Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures. <i>Arthritis Research and Therapy</i> , 2015, 17, 194.	1.6	48
41	Gender differences in irritable bowel syndrome: the interpersonal connection. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1478-1486.	1.6	21
42	Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. <i>Journal of Pain Research</i> , 2015, 8, 771.	0.8	20
43	Validity of the ≥50% Response Threshold in Treatment With NASHA/Dx Injection Therapy for Fecal Incontinence. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e70.	1.3	7
44	An Evidence-Based Review of Novel and Emerging Therapies for Constipation in Patients Taking Opioid Analgesics. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2014, 2, 38-46.	0.7	36
45	Linaclotide for the Treatment of Irritable Bowel Syndrome With Constipation: Is it Time to Reshuffle the Deck?. <i>Gastroenterology</i> , 2013, 145, 476-478.	0.6	3
46	The Utility of Probiotics in the Treatment of Irritable Bowel Syndrome: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2009, 104, 1033-1049.	0.2	323
47	<i>Bifidobacterium infantis</i> 35624: a novel probiotic for the treatment of irritable bowel syndrome. <i>Reviews in Gastroenterological Disorders</i> , 2009, 9, 7-15.	0.6	23